Literature DB >> 12358912

Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+/CD38- primitive haematopoietic progenitors.

Mohamad Mohty1, Daniel Isnardon, Norbert Vey, Francine Brière, Didier Blaise, Daniel Olive, Béatrice Gaugler.   

Abstract

Myeloid and plasmacytoid dendritic cells (MDC, PDC) play a key role in the initiation of immune responses. We found a reduction of DC subsets among 20 chronic myeloid leukaemia (CML) patients in chronic phase (MDC, mean, 0.10% +/- 0.10, P = 0.02; PDC, mean, 0.11% +/- 0.08, P = 0.006 versus controls). The maintenance of blood DC correlated with the presence of high percentages of circulating CD34+/CD38- progenitors that were able to give rise in vitro to CD1a+ DC. The reduced DC numbers may contribute to leukaemia escape from immune control and restoration of DC may be a goal for CML immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358912     DOI: 10.1046/j.1365-2141.2002.03831.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

Review 1.  The plasmacytoid monocyte/interferon producing cells.

Authors:  Fabio Facchetti; William Vermi; David Mason; Marco Colonna
Journal:  Virchows Arch       Date:  2003-10-28       Impact factor: 4.064

Review 2.  Regulation of myelopoiesis by the transcription factor IRF8.

Authors:  Tomohiko Tamura; Daisuke Kurotaki; Shin-ichi Koizumi
Journal:  Int J Hematol       Date:  2015-03-07       Impact factor: 2.490

3.  Low expression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in non-Hodgkin lymphoma and a significant correlation with β2-microglobulin.

Authors:  Dongbing Ding; Wenbin Chen; Changfu Zhang; Zhe Chen; Yanmei Jiang; Ziyi Yang; Xudong Jiang; Yunfei Zuo; Shuangyi Ren
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

4.  Chronic Myelocytic Leukemia (CML) Patient-Derived Dendritic Cells Transfected with Autologous Total RNA Induces CML-Specific Cytotoxicity.

Authors:  Li Yu; Ting Hu; Tian Zou; Qingzhi Shi; Guoan Chen
Journal:  Indian J Hematol Blood Transfus       Date:  2016-01-21       Impact factor: 0.900

Review 5.  Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies.

Authors:  John Joson Ng; S Tiong Ong
Journal:  Curr Hematol Malig Rep       Date:  2022-10-19       Impact factor: 4.213

Review 6.  Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.

Authors:  Taylor T Chrisikos; Yifan Zhou; Natalie Slone; Rachel Babcock; Stephanie S Watowich; Haiyan S Li
Journal:  Mol Immunol       Date:  2018-03-15       Impact factor: 4.407

Review 7.  Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.

Authors:  Amy Hughes; Agnes S M Yong
Journal:  Front Immunol       Date:  2017-04-24       Impact factor: 7.561

Review 8.  Can Dendritic Cell Vaccination Prevent Leukemia Relapse?

Authors:  Liam J O'Brien; Camille Guillerey; Kristen J Radford
Journal:  Cancers (Basel)       Date:  2019-06-22       Impact factor: 6.575

9.  Acute Lymphoblastic Leukaemia Cells Impair Dendritic Cell and Macrophage Differentiation: Role of BMP4.

Authors:  Jaris Valencia; Lidia M Fernández-Sevilla; Alberto Fraile-Ramos; Rosa Sacedón; Eva Jiménez; Angeles Vicente; Alberto Varas
Journal:  Cells       Date:  2019-07-14       Impact factor: 6.600

Review 10.  Dendritic cell-based immunotherapy for myeloid leukemias.

Authors:  Christian M Schürch; Carsten Riether; Adrian F Ochsenbein
Journal:  Front Immunol       Date:  2013-12-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.